Pirfenidone attenuates bladder fibrosis and mitigates deterioration of bladder function in a rat model of partial bladder outlet obstruction

Molecular Medicine Reports

Volumn 12, Issue 3, 2015, Pages 3639-3647

  Duan, Liu Jian ^a   Qi, Jun ^a   Huang, Tao ^a   Gu, Xin ^a   Xu, Ding ^a   Kong, Xiang Jie ^a   Qian, Xiao Qiang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Bladder fibrosis; Extracellular matrix; Growth factor; Partial bladder outlet obstruction; Pirfenidone

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CARBOXYMETHYLCELLULOSE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CONNECTIVE TISSUE GROWTH FACTOR; ELASTIN; FIBROBLAST GROWTH FACTOR 2; PIRFENIDONE; TRANSFORMING GROWTH FACTOR BETA1; PYRIDONE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMICAL ANALYSIS; BLADDER CAPACITY; BLADDER DISEASE; BLADDER FIBROSIS; BLADDER FUNCTION; BLADDER NECK STENOSIS; CONTROLLED STUDY; CYSTOMETRY; EXTRACELLULAR MATRIX; FIBROSIS; HISTOPATHOLOGY; MALE; MICTURITION; NONHUMAN; PARTIAL BLADDER OUTLET OBSTRUCTION; PROTEIN EXPRESSION; RAT; ANIMAL; BLADDER; DISEASE MODEL; DRUG EFFECTS; PATHOLOGY; SPRAGUE DAWLEY RAT; URINARY BLADDER NECK OBSTRUCTION;

RATTUS;

ANIMALS; DISEASE MODELS, ANIMAL; FIBROSIS; MALE; PYRIDONES; RATS, SPRAGUE-DAWLEY; URINARY BLADDER; URINARY BLADDER NECK OBSTRUCTION;

EID: 84935523555     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3814     Document Type: Article

References (37)

1. Metcalfe PD, Wang J, Jiao H, et al: Bladder outlet obstruction: progression from inflammation to fibrosis. Bju Int 106:1686-1694, 2 010.
2. Baskin LS, Sutherland RS, Thomson AA, et al: Growth factors and receptors in bladder development and obstruction. Lab Invest 75:157-166, 1996.
3. Kim JC, Yoon J Y, Seo SI, et al: Effects of partial bladder outlet obstruction and its relief on types I and III collagen and detrusor contractility in the rat. Neurourol Urodyn 19:29-42, 2000.
4. Kaplan E P, Richier JC, Howard PS, et al: Type III collagen messenger RNA is modulated in non-compliant human bladder tissue. J Urol 157:2366-2369, 1997.
5. Wick G, Backovic A, Rabensteiner E, et al: The immunology of fibrosis: innate and adaptive responses. Trends Immunol 31:110-119, 2010.
6. Iyer SN, Margolin SB, Hyde DM and Giri SN: Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model. Exp Lung Res 24:119-132, 1998.
7. Kehrer JP and Margolin SB: Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice. Toxicol Lett 90:125-132, 1997.
8. Azuma A, Nukiwa T, Tsuboi E, et al: Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171:1040-1047, 2005.
9. Navarro-Partida J, Martinez-Rizo Ab, Gonzalez-Cuevas J, Arrevillaga-Boni G, Ortiz-Navarrete V and Armaendariz-Borunda J:: Pirfenidone restricts Th2 differentiation in vitro and limits Th2 response in experimental liver fibrosis. Eur J Pharmacol 678:71-77, 2012.
10. García L, Hernández I, Sandoval A, et al: Pirfenidone effectively reverses experimental liver fibrosis. J Hepatol 37:797-805, 2002.
11. Chen JF, Ni HF, Pan MM, et al: Pirfenidone inhibits macrophage infiltration in 5/6 nephrectomized rats. Am J Physiol Renal Physiol 304:F676-F685, 2013.
12. Shi Q, Liu X, Bai Y, et al: In vitro effects of pirfenidone on cardiac fibroblasts: Proliferation, myofibroblast differentiation, migration and cytokine secretion. PLoS One 6:e28134, 2011.
13. Armaendariz-Borunda J, Lyra-Gonzalez I, Medina-Preciado D, et al: A controlled clinical trial with pirfenidone in the treatment of pathological skin scarring caused by burns in pediatric patients. Ann Plast Surg 68:22-28, 2012.
14. Zhao XY, Zeng X, Li XM, et al: Pirfenidone inhibits carbon tetrachloride- and albumin complex-induced liver fibrosis in rodents by preventing activation of hepatic stellate cells. Clin Exp Pharmacol Physiol 36:963-968, 2009.
15. Iyer SN, Gurujeyalakshmi G and Giri SN: Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 291:367-373, 1999.
16. Liu F, Yao L, Yuan J, et al: Protective effects of inosine on urinary bladder function in rats with partial bladder outlet obstruction. Urology 73:1417-1422, 2009.
17. Kim JW, Jang HA, Bae JH and Lee JG: Effects of coenzyme Q10 on bladder dysfunction induced by chronic bladder ischemia in a rat model. J Urol 189:2371-2376, 2013.
18. Oku H, Shimizu T, Kawabata T, et al: Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 590:400-408, 2008.
19. Parekh A, Long RA, Chancellor MB and Sacks MS: Assessing the effects of transforming growth factor-beta1 on bladder smooth muscle cell phenotype. II. Modulation of collagen organization. J Urol 182:1216-1221, 2009.
20. Cortivo R, Pagano F, Passerini G, et al: Elastin and collagen in the normal and obstructed urinary bladder. Br J Urol 53:134-137, 1981.
21. Ewalt DH, Howard PS, Blyth B, et al: Is lamina propria matrix responsible for normal bladder compliance? J Urol 148:544-549, 1992.
22. Djavan B, Lin V, Kaplan EP, et al: Decreased elastin gene expression in noncompliant human bladder tissue: a competitive reverse transcriptase-polymerase chain reaction analysis. J Urol 160:1658-1662, 1998.
23. Toosi KK, Nagatomi J, Chancellor MB and Sacks MS: The effects of long-term spinal cord injury on mechanical properties of the rat urinary bladder. Ann Biomed Eng 36:1470-1480, 2008.
24. Bai J, Liu XS, Xu YJ, Zhang ZX, Xie M and Ni W: Extracellular signal-regulated kinase activation in airway smooth muscle cell proliferation in chronic asthmatic rats. Sheng Li Xue Bao 59:311-318, 2007
25. Schultz K, Murthy V, Tatro JB and Beasley D: Endogenous interleukin-1 alpha promotes a proliferative and proinflammatory phenotype in human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 292:H2927-H2934, 2007
26. Runyan CE, Poncelet AC and Schnaper HW: TGF-beta receptor-binding proteins: complex interactions. Cell Signal 18:2077-2088, 2006.
27. Leask A and Abraham DJ: TGF-beta signaling and the fibrotic response. FASEB J 18:816-827, 2004
28. Howard PS, Kucich U, Coplen DE and He Y: Transforming growth factor-beta1-induced hypertrophy and matrix expression in human bladder smooth muscle cells. Urology 66:1349-1353, 2005
29. Barendrecht MM, Mulders AC, van der Poel H, et al: Role of transforming growth factor beta in rat bladder smooth muscle cell proliferation. J Pharmacol Exp Ther 322:117-122, 2007
30. Schaefer CJ, Ruhrmund DW, Pan L, et al: Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev 20:85-97, 2011.
31. Salazar-Montes A, Ruiz-Corro L, López-Reyes A, et al: Potent antioxidant role of pirfenidone in experimental cirrhosis. Eur J Pharmacol 595:69-77, 2008.
32. Oku H, Nakazato H, Horikawa T, et al: Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pharmacol 446:167-176, 2002.
33. Tada S, Nakamuta M, Enjoji M, et al: Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. Clin Exp Pharmacol Physiol 28:522-527, 2001.
34. Simone NL, Soule BP, Gerber L, et al: Oral pirfenidone in patients with chronic fibrosis resulting from radiotherapy: a pilot study. Radiat Oncol 2:19, 2007.
35. Walker JE, Giri SN and Margolin SB: A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis. Mult Scler 11:149-158, 2005.
36. Alcántar-Díaz BE, Gómez-Meda BC, Zúñiga-González GM, et al: Genotoxic evaluation of pirfenidone using erythrocyte rodent micronucleus assay. Food Chem Toxicol 50:2760-2765, 2012.
37. Pandita RK, Fujiwa ra M, Alm P and Andersson KE: Cystometric evaluation of bladder function in non-anesthetized mice with and without bladder outlet obstruction. J Urol 164:1385-1389, 2000.